Business
Telix (ASX:TLX) share price slips despite priority review status
The Telix Pharmaceuticals Ltd (ASX: TLX) share price is slipping today, down 2.5% in afternoon trading.
This comes despite the company reporting it had received priority review status from Australia’s Therapeutic Goods Administration (TGA) for its prostate cancer imaging product, TLX591-CDx.
The priority review provides Telix with a fast-tracked timeframe of 150 working days for its product dossier review and approval.
It’s possible this news was already factored into the share price. Telix shares soared 121% higher in the month of November, and the share price is up 152% year-to-date. By comparison, the S&P/ASX 200 Index (ASX: XJO) is flat since 2 January.
What does Telix Pharmaceuticals do?
Telix Pharmaceuticals is a…
-
General16 hours agoChina was the big disruptor in our region. Now the US is determined to take that title
-
General16 hours agoSpaceX to invest $3 billion in Musk’s xAI startup
-
Noosa News22 hours agoFrench women charged with smuggling $29m of meth into Australia
-
General20 hours agoAlgal bloom ‘disaster’ prompts royal commission call as impact spreads to mussel farms